CD274 and neoplasm: Fortunately, some biomarkers have successfully predicted the efficacy of ICI treatment to various degrees (8), such as PD-L1 expression, tumor mutation burden (TMB), neoantigen load (NAL), mismatch repair (MMR) status, microsatellite instability (MSI) status, specific gene mutations, and tumor-infiltrating lymphocytes (TILs).